Cytodyn Inc. (CYDY) Stock Price & Analysis
Cytodyn Inc. (CYDY) fell 4.76% to USD 0.2 as of July 25, 2026 at 11:58 UTC, according to Nexqual real-time market data.
CYDY last closed at USD 0.21; the session ranged USD 0.2–0.22 on volume of 1,230,726 shares. Market capitalization is $273.95M, with a 52-week range of USD 0.19–0.4 (OQB). Source: Nexqual, July 25, 2026 at 11:58 UTC.
Key Statistics (as of July 25, 2026 at 11:58 UTC)
| Price | USD 0.2 |
|---|---|
| Change | ▼ 4.76% (down) |
| Previous Close | USD 0.21 |
| Open | USD 0.21 |
| Day Range | USD 0.2 – 0.22 |
| 52-Week Range | USD 0.19 – 0.4 |
| Volume | 1,230,726 shares |
| Market Cap | $273.95M |
| Exchange | OQB |
Technical Analysis (CYDY)
Nexqual's technical model rates CYDY "SELL" based on 2 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 11:58 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 26.5 (oversold) |
| vs SMA50 | Below (USD 0.27) |
| MACD | -0.02 (negative) |
Analyst Ratings (CYDY)
Wall Street analysts rate CYDY "None", per Nexqual as of July 25, 2026 at 11:58 UTC.
| Consensus Rating | None |
|---|
Earnings (CYDY)
| Next Earnings Date | 2026-07-27 |
|---|
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2021-02-28 | USD -0.05 vs est -0.05 ▲ beat |
| 2020-11-30 | USD -0.06 vs est -0.05 ▼ miss |
| 2020-08-31 | USD -0.06 vs est -0.06 ▲ beat |
| 2020-05-31 | USD -0.07 vs est -0.05 ▼ miss |
Source: Nexqual, July 25, 2026 at 11:58 UTC.
Financials & Fundamentals (CYDY)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| Current Ratio | 0.37 |
| Total Cash | $15.65M |
| Total Debt | $28.82M |
| Free Cash Flow | $-4.85M |
Source: Nexqual, July 25, 2026 at 11:58 UTC.
Financial Health Score (CYDY)
Nexqual rates Cytodyn Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 11:58 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $16M cash vs $29M debt |
| Cash Flow | Weak — Operating cash flow -$18M |
| Efficiency | Mixed — No data |
Ownership (CYDY)
| Insider Ownership | +0.01% |
|---|---|
| Institutional Ownership | +0.01% |
| Shares Outstanding | 1.37B |
| Float | 1.37B |
Source: Nexqual, July 25, 2026 at 11:58 UTC.
Leadership (CYDY)
Cytodyn Inc. is led by Jacob P. Lalezari (age 65), Chief Executive Officer, per Nexqual as of July 25, 2026 at 11:58 UTC.
| Chief Executive Officer | Jacob P. Lalezari (age 65) |
|---|
From Cytodyn Inc.'s Latest SEC 10-K Filing (filed 2025-07-25)
Key Strengths & Strategy (as disclosed to the SEC)
- CytoDyn Inc., a clinical-stage biotechnology company, develops treatments for multiple therapeutic indications.
- It is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19.
- The company's leronlimab is currently under phase 2 development for the treatment of micro-satellite stable colorectal cancer, and solid tumors in oncology, such as metastatic triple-negative breast cancer.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RLFTF | MindMaze Therapeutics Holding S | USD 0.2 | ▲ 4.17% |
| VXRT | Vaxart, Inc. | USD 0.5 | ▲ 4.17% |
| CODX | Co-Diagnostics, Inc. | USD 2.1 | ▼ 7.89% |
| IBIO | iBio, Inc. | USD 1.43 | ▲ 3.62% |
| SRNE | Sorrento Therapeutics, Inc. | USD 0 | ▼ 100% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 11:58 UTC. This page is informational and not investment advice.